|
1
|
Araujo-Castro M, Berrocal VR and
Pascual-Corrales E: Pituitary tumors: Epidemiology and clinical
presentation spectrum. Hormones (Athens). 19:145–155. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gittleman H, Ostrom QT, Farah PD, Ondracek
A, Chen Y, Wolinsky Y, Kruchko C, Singer J, Kshettry VR, Laws ER,
et al: Descriptive epidemiology of pituitary tumors in the United
States, 2004–2009. J Neurosurg. 121:527–535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tatsi C and Stratakis CA: The genetics of
pituitary adenomas. J Clin Med. 9:302019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerber DE: Targeted therapies: A new
generation of cancer treatments. Am Fam Physician. 77:311–319.
2008.PubMed/NCBI
|
|
5
|
Zhou C: Pituitary tumors: Role of
pituitary tumor-transforming gene-1 (PTTG1). Tumors of the Central
Nervous System, Volume 10: Pineal, Pituitary, and Spinal Tumors.
Hayat MA: Springer; Dordrecht: pp. 203–214. 2013, View Article : Google Scholar
|
|
6
|
Pei L and Melmed S: Isolation and
characterization of a pituitary tumor-transforming gene (PTTG). Mol
Endocrinol. 11:433–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Donangelo I, Gutman S, Horvath E, Kovacs
K, Wawrowsky K, Mount M and Melmed S: Pituitary tumor transforming
gene overexpression facilitates pituitary tumor development.
Endocrinology. 147:4781–4791. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chesnokova V, Kovacs K, Castro AV, Zonis S
and Melmed S: Pituitary hypoplasia in Pttg-/- mice is protective
for Rb+/- pituitary tumorigenesis. Mol Endocrinol. 19:2371–2379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rahman S and Islam R: Mammalian Sirt1:
Insights on its biological functions. Cell Commun Signal. 9:112011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li X: SIRT1 and energy metabolism. Acta
Biochim Biophys Sin (Shanghai). 45:51–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bordone L and Guarente L: Calorie
restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev
Mol Cell Biol. 6:298–305. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pagans S, Pedal A, North BJ, Kaehlcke K,
Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney
MW, et al: SIRT1 regulates HIV transcription via Tat deacetylation.
PLoS Biol. 3:e412005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rajman L, Chwalek K and Sinclair DA:
Therapeutic potential of NAD-boosting molecules: The in vivo
evidence. Cell Metab. 27:529–547. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thompson AD III and Kakar SS: Insulin and
IGF-1 regulate the expression of the pituitary tumor transforming
gene (PTTG) in breast tumor cells. FEBS Lett. 579:3195–3200. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH,
Lee JE, Wang C, Brindle PK, Dent SY and Ge K: Distinct roles of
GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in
nuclear receptor transactivation. EMBO J. 30:249–262. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang W, Prakash C, Sum C, Gong Y, Li Y,
Kwok JJ, Thiessen N, Pettersson S, Jones SJ, Knapp S, et al:
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II
serine 2 phosphorylation in human CD4+ T cells. J Biol Chem.
287:43137–43155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi X, Liu C, Liu B, Chen J, Wu X and Gong
W: JQ1: A novel potential therapeutic target. Pharmazie.
73:491–493. 2018.PubMed/NCBI
|
|
19
|
Grbesa I, Pajares MJ, Martinez-Terroba E,
Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio
R and Montuenga LM: Expression of sirtuin 1 and 2 is associated
with poor prognosis in non-small cell lung cancer patients. PLoS
One. 10:e01246702015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS,
Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis for breast
carcinoma. Hum Pathol. 42:204–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noguchi A, Kikuchi K, Zheng H, Takahashi
H, Miyagi Y, Aoki I and Takano Y: SIRT1 expression is associated
with a poor prognosis, whereas DBC1 is associated with favorable
outcomes in gastric cancer. Cancer Med. 3:1553–1561. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Sun K, Jiao S, Cai N, Zhao X, Zou
H, Xie Y, Wang Z, Zhong M and Wei L: High levels of SIRT1
expression enhance tumorigenesis and associate with a poor
prognosis of colorectal carcinoma patients. Sci Rep. 4:74812014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung-Hynes B, Nihal M, Zhong W and Ahmad
N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A
target for prostate cancer management via its inhibition? J Biol
Chem. 284:3823–3832. 2009.PubMed/NCBI
|
|
24
|
Marshall GM, Liu PY, Gherardi S, Scarlett
CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, et al:
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop
involving the effects of MKP3 and ERK on N-Myc protein stability.
PLoS Genet. 7:e10021352011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S,
Yu TK, Kim KM, Park HS, Lee JH, Moon WS, et al: Expression of SIRT1
and DBC1 is associated with poor prognosis of soft tissue sarcomas.
PLoS One. 8:e747382013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen IC, Chiang WF, Huang HH, Chen PF,
Shen YY and Chiang HC: Role of SIRT1 in regulation of
epithelial-to-mesenchymal transition in oral squamous cell
carcinoma metastasis. Mol Cancer. 13:2542014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong S and Weber JD: Deacetylation of the
retinoblastoma tumour suppressor protein by SIRT1. Biochem J.
407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menssen A, Hydbring P, Kapelle K,
Vervoorts J, Diebold J, Lüscher B, Larsson LG and Hermeking H: The
c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and
the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad
Sci USA. 109:E187–E196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim JH, Lee YM, Chun YS, Chen J, Kim JE
and Park JW: Sirtuin 1 modulates cellular responses to hypoxia by
deacetylating hypoxia-inducible factor 1alpha. Mol Cell.
38:864–878. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garcia-Peterson LM and Li X: Trending
topics of SIRT1 in tumorigenicity. Biochim Biophys Acta Gen Subj.
1865:1299522021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rauh D, Fischer F, Gertz M,
Lakshminarasimhan M, Bergbrede T, Aladini F, Kambach C, Becker CF,
Zerweck J, Schutkowski M and Steegborn C: An acetylome peptide
microarray reveals specificities and deacetylation substrates for
all human sirtuin isoforms. Nat Commun. 4:23272013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marmorstein R and Zhou MM: Writers and
readers of histone acetylation: Structure, mechanism, and
inhibition. Cold Spring Harb Perspect Biol. 6:a0187622014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vlotides G, Eigler T and Melmed S:
Pituitary tumor-transforming gene: Physiology and implications for
tumorigenesis. Endocr Rev. 28:165–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zou H, McGarry TJ, Bernal T and Kirschner
MW: Identification of a vertebrate sister-chromatid separation
inhibitor involved in transformation and tumorigenesis. Science.
285:418–422. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang
Y, Fang Y and Fang D: Overview of histone modification. Adv Exp Med
Biol. 1283:1–16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luense LJ, Donahue G, Lin-Shiao E, Rangel
R, Weller AH, Bartolomei MS and Berger SL: Gcn5-mediated histone
acetylation governs nucleosome dynamics in spermiogenesis. Dev
Cell. 51:745–758.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Patel JH, Du Y, Ard PG, Phillips C,
Carella B, Chen CJ, Rakowski C, Chatterjee C, Lieberman PM, Lane
WS, et al: The c-MYC oncoprotein is a substrate of the
acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol.
24:10826–10834. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y,
Deng A, Chen J, Wang G, Zhu S and Kang J: Lysine acetyltransferase
GCN5 potentiates the growth of non-small cell lung cancer via
promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol
Chem. 288:14510–14521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gokani S and Bhatt LK: Bromodomains: A
novel target for the anticancer therapy. Eur J Pharmacol.
911:1745232021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang H, Wei L, Xun Y, Yang A and You H:
BRD4: An emerging prospective therapeutic target in glioma. Mol
Ther Oncolytics. 21:1–14. 2021. View Article : Google Scholar : PubMed/NCBI
|
